Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 12, 2008, Pages 1454-1460

  Stringer, Kathleen A ^a,b,c   Tobias, Meghan ^b   Dunn, John S ^b,d   Campos, Jackie ^c   Van Rheen, Zachary ^b   Mosharraf, Mitra ^c   Nayar, Rajiv ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HTD Biosystems   (United States)

^d Inverness Medical Professional Diagnostics   (United States)

Author keywords

B6C3F1 mice; Haemorrhage; Nebulization; Pulmonary drug delivery; Tissue plasminogen activator

Indexed keywords

LACTATE DEHYDROGENASE; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOCRIT; HISTOPATHOLOGY; LUNG HEMORRHAGE; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PNEUMONIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; SEX DIFFERENCE; SINGLE DRUG DOSE; STORAGE TEMPERATURE;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; LONGITUDINAL STUDIES; LUNG; MALE; MICE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 55349089963     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05011.x     Document Type: Article

References (36)

1. Cooper P, Potter S, Mueck B, Yousefi S, Jarai G. Identification of genes induced by inflammatory cytokines in airway epithelium. Am. J. Physiol. Lung Cell Mol. Physiol. 2001 280 : L841 52.
2. Stringer KA, Dunn JS, Gustafson DL. Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene. Clin. Exp. Pharmacol. Physiol. 2004 31 : 327 30.
3. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J. Biol. Chem. 2006 281 : 2120 7.
4. Renckens R, Roelofs JJ, Florquin S et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J. Immunol. 2006 177 : 1189 96.
5. Stringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic. Biol. Med. 1997 22 : 985 8.
6. Stringer KA. Tissue plasminogen activator inhibits reactive oxygen species production by macrophages. Pharmacotherapy 2000 20 : 375 9.
7. Stringer KA, Lindenfeld J, Repine AJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 1997 21 : 27 34.
8. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic. Biol. Med. 1998 25 : 184 8.
9. MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 2007 27 : 860 73.
10. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol Biol. 2005 33 : 319 27.
11. Dunn JS, Nayar R, Campos J et al. Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm. Res. 2005 22 : 1700 7.
12. Gardell SJ. The search for the ideal thrombolytic agent: Maximize the benefit and minimize the risk. Toxicol. Pathol. 1993 21 : 190 8.
13. Simoons ML. Risk-benefit of thrombolysis. Cardiol. Clin. 1995 13 : 339 45.
14. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 1981 46 : 561 5.
15. Kueltzo L. Ultraviolet absorption spectroscopy. In : Jiskoot W, Crommelin DJ (eds). Methods for Structural Analysis of Protein Pharmaceuticals. American Association of Pharmaceutical Scientists, Arlington. 2005 1 25.
16. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 2006 95 : 1084 96.
17. Sherman PM, Lawrence DA, Verhamme IM, Paielli D, Shore JD, Ginsburg D. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J. Biol. Chem. 1995 270 : 9301 6.
18. MacDonald ME, van Zonneveld AJ, Pannekoek H. Functional analysis of the human tissue-type plasminogen activator protein: The light chain. Gene 1986 42 : 59 67.
19. van Zonneveld AJ, Veerman H, MacDonald ME, van Mourik JA, Pannekoek H. Structure and function of human tissue-type plasminogen activator (t-PA). J. Cell. Biochem. 1986 32 : 169 78.
20. Kuschel M, Neumann T, Barthmaier P, Kratzmeier M. Use of lab-on-a-chip technology for protein sizing and quantitation. J. Biol. Tech. 2002 13 : 172 8.
21. Lauer JE, Heger JJ, Mirro MJ. Hemorrhagic complications of thrombolytic therapy. Chest 1995 108 : 1520 3.
22. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: A review of the risk factors. Cerebrovasc. Dis. 2007 24 : 1 10.
23. Kristof AS, Goldberg P, Laubach V, Hussain SNA. Role of inducible nitric oxide synthase in endotoxin-induced acute lung injury. Am. J. Respir. Cell Mol. Biol. 1998 158 : 1883 9.
24. Parker JC, Townsley MI. Evaluation of lung injury in rats and mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2004 286 : L231 46.
25. Stringer KA, Freed BM, Dunn JS, Sayers S, Gustafson DL, Flores SC. Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs. Free Radic. Biol. Med. 2004 37 : 1527 33.
26. Smith PK, Krohn RI, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985 150 : 76 85.
27. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 1988 115 : 61 9.
28. Card JW, Carey MA, Bradbury JA et al. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J. Immunol. 2006 177 : 621 30.
29. Reinhard C, Eder G, Fuchs H, Ziesenis A, Heyder J, Schulz H. Inbred strain variation in lung function. Mamm. Genome 2002 13 : 429 37.
30. Li YJ, Kawada T, Matsumoto A et al. Airway inflammatory responses to oxidative stress induced by low-dose diesel exhaust particle exposure differ between mouse strains. Exp. Lung Res. 2007 33 : 227 44.
31. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007 6 : 67 74.
32. Munster AM, Rasmussen L, Sidelmann J, Ingemann Jensen J, Bech B, Gram J. Effects of inhaled plasminogen activator on the balance between coagulation and fibrinolysis in traumatized pigs. Blood Coagul. Fibrinolysis 2002 13 : 591 601.
33. Su X, Looney M, Robriquet L, Fang X, Matthay MA. Direct visual instillation as a method for efficient delivery of fluid into the distal airspaces of anesthetized mice. Exp. Lung Res. 2004 30 : 479 93.
34. Lynch DW, Placke ME, Persing RL, Ryan MJ. Thirteen-week inhalation toxicity of N,N-dimethylformamide in F344/N rats and B6C3F1 mice. Toxicol. Sci. 2003 72 : 347 58.
35. Irwin RD. A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen. J. Appl. Toxicol. 2006 26 : 72 80.
36. Dill J, Fuciarelli A, Lee K, Mellinger K, Burka L, Roycroft J. Toxicokinetics of propylene glycol mono-t-butyl ether following intravenous or inhalation exposure in rats and mice. Inhal. Toxicol. 2004 16 : 271 90.